- NCIt
- C4925
Loading cancer entity…
Loading cancer entity…
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01593241 | Therapy De-escalation in Seminoma Stage IIA/B | terminated | Phase 2 | 120 | Swiss Cancer InstituteOTHER | 2 | Feb 13, 2025 | clinicaltrials |
| NCT01055067 | ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors | terminated | Phase 2 | 27 | Daiichi SankyoINDUSTRY | 3 | Apr 6, 2021 | clinicaltrials |
| NCT02689219 |
| Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
| terminated |
| Phase 2 |
| 18 |
| Nabil AdraOTHER |
| 1 |
| Dec 10, 2019 |
| clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 13, 2025source: clinicaltrials